Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very healthy...yet frustrating consolidation. Nothing great comes easy. People selling will be kicking themselves. Oh ya, and thanks for all the cheap shares yesterday and today.
With that said, I wouldn't want to be waiting on the sidelines waiting for a dip later today or next week, lol
Soon...
CANT on the bid at .0063 and on the ask at .2566....could be time for CDEL to get the heck out of the way.
100 trade at .00635, mm signal -> I need shares
It's right there...I can see it on the horizon! CDEL is making it hard on all of us! He's been pulling shares out of thin air for 2 days now.
Something's Coming!
CDEL still playing the ax, comical
Thin thin thin on the ask, just need a little volume
I think you hit the nail on the head Fly!
Fake MM walls are coming down, LOL
EXPLODE EXPLODE EXPLODE!!!
Yes, this is dying to bust lose right now!! I wish the MMs would just let it run to where it should be!
I see some weird games being played by the MMs right now...they have to be taking a hint by now that this is ready for blast off
Does anyone elses Level 2 look strange this morning or is it just mine? I can't see what MMs are on bid and ask, it is only showing numbers...and it's only doing that for NPHC.
Financing
LOL, sorry WESWIX, my excitement for NPHC has officially gone through the roof!
13g is required when a company buys more than 5%, so yes it should be 9.78
Absolutely!!! I believe it explains a lot of the crazy MM action we've been seeing too, Conventry has been accumulating and now owns nearly 10% of nphc. I'd say they have faith in the company and big things are coming!
Definitely one of the whales accumulating shares
Schedule 13G is an SEC form similar to the Schedule 13D used to report a party's ownership of stock that is over 5% of the company. Schedule 13G is shorter and requires less information from the filing party.
There is a company that has bought 182m shares of nphc
AD Line is still tipping up after today. Shares going into stronger hands. The majority of shares today were traded in the 006s. Past 11 trading days volume now at 1,057,903,576. It was obvious today that there were sellers taking some profits but also the whales did not want this taking off too quick (ie CDEL putting up 1mil share blocks constantly and undercutting the ask). It's frustrating sometimes, but the way we are going up with daily consolidation and stair stepping is the best and strongest way to go up and keep the gains. I personally have not sold 1 single share due to all the outstanding DD, thanks to Fly, RSI, and Mav. Rik has a plan and is executing. Happy to be along for the ride!
$NPHC!
https://www.barchart.com/stocks/quotes/NPHC/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(20);SMA(200);SMA(100);SMA(50);SMA(10);ACCUM;RSI(14,100)&sym=NPHC&grid=1&height=500&studyheight=100
LOL, Good call brother!
I've got a headache man, these MMs are driving me nuts, LOL!
CDEL has been trying to push us down all day. I'm hoping he gets burned before EOD
There will be a volume surge to push this to 7s, just like there was when we crossed into 6s this morning. There are much larger forces at work here.
No gaps and no dilution
I agree, with only 2 points difference if we continue this trend we will cross Monday or Tuesday at the latest.
New HOD of the horizon! Bust through those 0065s!
Yes, it looks like a retail getting out or substantially lightening his load, oh well, put those shares in stronger hands
Intraday consolidation all the way up. Stair stepping. Beautiful
I have a feeling it will hit the wires once the market opens.
BOOM!
Nutra Pharma Announces Nyloxin® Distribution Agreement for Australia and New Zealand
February 1, 2018
February 1, 2018 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis (MS) and HIV and that also markets the over-the-counter (OTC) pain drugs; Nyloxin® and Pet Pain-Away™, announced today that they have signed a definitive Distribution Agreement with the Australian company, Pharmachal PTY LTD to market and distribute Nyloxin® in Australia and New Zealand.
“We recently announced our domestic efforts to increase sales and distribution of Nyloxin," stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This included the new website, web promotions and our application to be added to the Federal Supply Schedule for sales to US governmental agencies,” he continued. “I'm excited to announce that we have also been working to promote our products internationally. We have been moving forward with our efforts in Canada and India – and we are now announcing our agreement with Pharmachal to be our exclusive distributor of Nyloxin in Australia and New Zealand. Once they receive regulatory approval through the TGA, they will be able to warehouse, market and distribute Nyloxin throughout their territories. We believe this will allow for broad distribution and marketing in that region by the end of this year,” he concluded.
According to Euromonitor, the OTC analgesics drug category in Australia was worth US$627 million in 2017. The new ban on OTC sales of codeine in Australia is expected to be the biggest factor impacting growth in analgesics. In December 2016, Australia’s drug regulator, the Therapeutic Goods Administration (TGA), shifted painkillers containing codeine to be listed as schedule one drugs that can only be sold with a prescription due to concerns about the addictive nature of codeine. While the total analgesic market is expected to shrink over the next ten years, the OTC market is expected to grow, especially with the launch of Amazon in Australia this year. As a result of the codeine ban, consumers are increasingly expected to turn to alternative combination analgesics that require no prescription, to avoid visiting a doctor.
“We are extremely pleased to be working with Nutra Pharma Corp.," commented Charles Fridlender, CEO of Pharmachal PTY LTD. "We believe that Nyloxin could be a disruptive product in the Australian marketplace. This is especially true with the recent crackdown on opiates in Australia and throughout the world. This non-opiate, non-narcotic product could have a ready audience in our markets," he continued. "We are already working with our regulatory authorities to get Nyloxin approved for re-sale in the Australian market as soon as possible. We expect to make the products available this calendar year,” he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
About Pharmachal PTY LTD.
Pharmachal is a pharmaceutical, medical device and veterinary company based in Melbourne, Australia. The company develops, manufactures and distributes its products through medical specialists and will soon distribute direct to customers in Australia and internationally. Pharmachal has developed a patented mini emulsion delivery system in a spray for oral and dermal application. Only the best ingredients and materials are chosen for Phamachal products, based on rigorous research and exacting attention to detail. For additional information about Pharmachal, visit:
https://www.pharmachal.com
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The distribution agreement with Pharmachal should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Chart looking great. Based on our trading pattern, we will have a green day tomorrow...if we get any type of news we could push copper IMO. The volume from the last 10 trading sessions is nearly 1 billion shares, there is a strong possibility this float is or could be locked soon. By the action we saw today, MMs are scrambling and available shares are scarce. IMO, I see copper before the closing bell on Friday with or without updates.
Shares traded in 002-003 range
1/18 - 268,806,016
1/19 - 116,616,496
1/22 - 87,862,704
1/23 - 30,928,500
1/24 - 35,893,900
1/25 - 50,806,900
TOTAL 590,914,516
Shared traded 003-005 range
1/26 - 175,720,800
1/29 - 92,070,304
1/30 - 59,919,200
1/31 - 32,221,237
TOTAL 359,931,541
GRAND TOTAL - 950,846,057
https://www.barchart.com/stocks/quotes/NPHC/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(50);SMA(100);SMA(20);SMA(200);RSI(14,100);MFI(14,100);SMACD(12,26,9)&sym=NPHC&grid=1&height=500&studyheight=100